Clinical Trial Update: Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib plus nivolumab in unresectable, locally advanced, or metastatic hepatocellular carcinoma has completed and results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)
• OPDIVO (nivolumab)

Snippet

Sponsor: Robin Kate Kelley | Conditions: Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8 | Phase 2 | Status: COMPLETED | Results posted: 2025-02-11